Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 50 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 3350; iron oxide yellow; iron oxide red; polyvinyl alcohol; sodium stearylfumarate; lactose monohydrate; purified talc; microcrystalline cellulose; silicon dioxide; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; purified talc; iron oxide yellow; silicon dioxide; polyvinyl alcohol; macrogol 3350; sodium stearylfumarate; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; polyvinyl alcohol; microcrystalline cellulose; silicon dioxide; sodium stearylfumarate; titanium dioxide; macrogol 3350; purified talc - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - fluoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - dulaglutide -

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 100 mg) - capsule, hard - excipient ingredients: iron oxide red; gelatin; iron oxide yellow; dimeticone 350; sodium lauryl sulfate; pregelatinised maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 91.42 mg (equivalent: atomoxetine, qty 80 mg) - capsule, hard - excipient ingredients: iron oxide red; sodium lauryl sulfate; gelatin; iron oxide yellow; titanium dioxide; dimeticone 350; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine pamoate monohydrate, quantity: 483 mg (equivalent: olanzapine, qty 210 mg) - diluent, not applicable - excipient ingredients: carmellose sodium; mannitol; hydrochloric acid; polysorbate 80; sodium hydroxide; water for injections - zyprexa relprevv is a long acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilized during acute treatment with oral olanzapine. the effectiveness of zyprexa relprevv is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.